SCHEMBL5121677

SCHEMBL5121677

COc1ccc(CNC(=O)C2=NOC3(CCN(C(=S)Nc4ccccc4C(F)(F)F)CC3)C2)cc1OC

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
NAMPT P43490 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 2/20 0.40
PKM P14618 1/20 0.40
HTT P42858 2/20 0.40
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119733 0.91 KMT2A (0.46) KMT2ASMN1; SMN2GAAL3MBTL1NAMPT
SCHEMBL5120149 0.91 ALDH1A1 (0.42) KMT2ASMN1; SMN2GAAMAPTL3MBTL1
SCHEMBL5111528 0.89 GAA (0.42) LMNAKMT2ASMN1; SMN2GAAMAPT
SCHEMBL5119611 0.89 ALDH1A1 (0.42) LMNAKMT2ASMN1; SMN2GAAMAPT
SCHEMBL5120842 0.89 ALDH1A1 (0.43) LMNAKMT2ASMN1; SMN2GAAMAPT
SCHEMBL5125515 0.89 L3MBTL1 (0.43) KMT2ASMN1; SMN2GAAMAPTL3MBTL1
SCHEMBL1457254 0.88 LMNA (0.40) LMNAKMT2ASMN1; SMN2GAAMAPT
SCHEMBL5120134 0.87 SMN1; SMN2 (0.47) LMNAKMT2ASMN1; SMN2GAAMAPT
SCHEMBL5115065 0.87 MEN1 (0.43) LMNAKMT2ASMN1; SMN2GAAMAPT
SCHEMBL5125610 0.86 ALDH1A1 (0.47) LMNAKMT2ASMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs GRUENENTHAL GMBH (DE) 2008-09-04 US claimed
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs GRUENENTHAL GMBH (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs REN, PKD1, NR3C2 LMNA 421/4885KMT2A 4068/4885SMN1; SMN2 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.